Cited 3 times in
Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김상운 | - |
dc.contributor.author | 김성훈 | - |
dc.contributor.author | 김영태 | - |
dc.contributor.author | 남은지 | - |
dc.contributor.author | 선기은 | - |
dc.contributor.author | 이용재 | - |
dc.contributor.author | 이정윤 | - |
dc.contributor.author | 정대철 | - |
dc.date.accessioned | 2023-03-21T07:32:25Z | - |
dc.date.available | 2023-03-21T07:32:25Z | - |
dc.date.issued | 2022-07 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/193431 | - |
dc.description.abstract | To evaluate the additive effects of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval debulking surgery (IDS) in patients with advanced-stage ovarian cancer. From January 2015 to February 2019, 123 patients with stages IIIC-IV ovarian cancer were treated with neoadjuvant chemotherapy (NAC) followed by IDS with optimal cytoreduction. Forty-three patients received IDS with HIPEC and 80 patients had IDS without HIPEC. The median follow-up period was 34.4 months. No differences in baseline characteristics in patients were found between the two groups. The IDS with HIPEC group had fewer median cycles of chemotherapy (P = 0.002) than the IDS group. The IDS with HIPEC group had a higher rate of high surgical complexity score (P = 0.032) and higher rate of complete resection (P = 0.041) compared to the IDS group. The times to start adjuvant chemotherapy were longer in the IDS with HIPEC group compared to the IDS group (P < 0.001). Postoperative grade 3 or 4 complications were similar in the two groups (P = 0.237). Kaplan-Meier analysis showed that HIPEC with the IDS group had better progression-free survival (PFS) (P = 0.010), while there was no difference in overall survival between the two groups (P = 0.142). In the multivariate analysis, HIPEC was significantly associated with better PFS (HR, 0.60; 95% CI, 0.39 - 0.93). The addition of HIPEC to IDS resulted in longer PFS than IDS without HIPEC not affecting the safety profile. Further research is needed to evaluate the true place of HIPEC in the era of targeted treatments. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Frontiers Research Foundation | - |
dc.relation.isPartOf | FRONTIERS IN ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics and Gynecology (산부인과학교실) | - |
dc.contributor.googleauthor | Yong Jae Lee | - |
dc.contributor.googleauthor | Ki Eun Seon | - |
dc.contributor.googleauthor | Dae Chul Jung | - |
dc.contributor.googleauthor | Jung-Yun Lee | - |
dc.contributor.googleauthor | Eun Ji Nam | - |
dc.contributor.googleauthor | Sang Wun Kim | - |
dc.contributor.googleauthor | Sunghoon Kim | - |
dc.contributor.googleauthor | Young Tae Kim | - |
dc.identifier.doi | 10.3389/fonc.2022.936099 | - |
dc.contributor.localId | A00526 | - |
dc.contributor.localId | A00595 | - |
dc.contributor.localId | A00729 | - |
dc.contributor.localId | A01262 | - |
dc.contributor.localId | A06261 | - |
dc.contributor.localId | A05165 | - |
dc.contributor.localId | A04638 | - |
dc.contributor.localId | A03592 | - |
dc.relation.journalcode | J03512 | - |
dc.identifier.eissn | 2234-943X | - |
dc.identifier.pmid | 35965567 | - |
dc.subject.keyword | Advanced stage ovarian cancer | - |
dc.subject.keyword | hyperthermic intraperitoneal chemotherapy (hipec) | - |
dc.subject.keyword | interval debulking surgery (IDS) | - |
dc.subject.keyword | neoadjuvant chemotherapy (NAC) | - |
dc.subject.keyword | ovarian cancer | - |
dc.contributor.alternativeName | Kim, Sang Wun | - |
dc.contributor.affiliatedAuthor | 김상운 | - |
dc.contributor.affiliatedAuthor | 김성훈 | - |
dc.contributor.affiliatedAuthor | 김영태 | - |
dc.contributor.affiliatedAuthor | 남은지 | - |
dc.contributor.affiliatedAuthor | 선기은 | - |
dc.contributor.affiliatedAuthor | 이용재 | - |
dc.contributor.affiliatedAuthor | 이정윤 | - |
dc.contributor.affiliatedAuthor | 정대철 | - |
dc.citation.volume | 12 | - |
dc.citation.startPage | 936099 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN ONCOLOGY, Vol.12 : 936099, 2022-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.